Correction: CLN-978, a novel half-life extended CD19/CD3/HSA-specific T cell-engaging antibody construct with potent activity against B-cell malignancies with low CD19 expression
- PMID: 38101863
- PMCID: PMC10729079
- DOI: 10.1136/jitc-2023-007398corr1
Correction: CLN-978, a novel half-life extended CD19/CD3/HSA-specific T cell-engaging antibody construct with potent activity against B-cell malignancies with low CD19 expression
Erratum for
-
CLN-978, a novel half-life extended CD19/CD3/HSA-specific T cell-engaging antibody construct with potent activity against B-cell malignancies with low CD19 expression.J Immunother Cancer. 2023 Aug;11(8):e007398. doi: 10.1136/jitc-2023-007398. J Immunother Cancer. 2023. PMID: 37586770 Free PMC article.
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources